Biohaven Pharmaceutical

OverviewSuggest Edit

Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. Biohaven obtained licenses from Yale University School of Medicine and Massachusetts General Hospital regarding intellectual property relating to the use of certain glutamate modulating agents in the treatment of neuropsychiatric disorders. The mission of the company is to exploit advances over the past decade in the understanding of glutamate mechanisms involved in a variety of diseases. The company’s first drug candidate is being developed for orphan neurological disorders as well as treatment-resistant anxiety and depression. Biohaven has assembled a team of experts who have extensive experience in the development of therapeutic agents in this area and also comprise the originators at Yale University who discovered the therapeutic potential of glutamate modulation in anxiety and depression. Team members have designed and executed successful development programs testing a variety of agents in affective disorders, leading to first-cycle FDA approvals and successful commercialization.
TypePrivate
Founded2014
HQNew Haven, US
Websitebiohavenpharma.com

Latest Updates

Employees (est.) (Sept 2020)754
Cybersecurity ratingAMore

Key People/Management at Biohaven Pharmaceutical

Declan Doogan

Declan Doogan

Chairman and Director
Vlad Coric

Vlad Coric

Chief Executive Officer, Director
James Engelhart

James Engelhart

Chief Financial Officer
Kimberly Gentile

Kimberly Gentile

Senior Vice President, Clinical Operations
Gregory H. Bailey

Gregory H. Bailey

Director
Charles Conway

Charles Conway

Chief Scientific Officer
Show more

Biohaven Pharmaceutical Office Locations

Biohaven Pharmaceutical has an office in New Haven
New Haven, US (HQ)
215 Church St
Show all (1)

Biohaven Pharmaceutical Financials and Metrics

Summary Metrics

Founding Date

2014

Biohaven Pharmaceutical total Funding

$80 m

Biohaven Pharmaceutical latest funding size

$80 m

Time since last funding

4 years ago

Biohaven Pharmaceutical investors

Biohaven Pharmaceutical's latest funding round in November 2016 was reported to be $80 m. In total, Biohaven Pharmaceutical has raised $80 m
Show all financial metrics

Biohaven Pharmaceutical Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Biohaven Pharmaceutical Online and Social Media Presence

Embed Graph

Biohaven Pharmaceutical News and Updates

Thinking about trading options or stock in Broadcom, Biohaven Pharmaceutical, Lyft, Occidental Petroleum, or Tesla?

NEW YORK, June 18, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVGO, BHVN, LYFT, OXY, and TSLA. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Biohaven Pharmaceuticals Reports Second Quarter 2018 Financial And Recent Business Results

NEW HAVEN, Conn., Aug. 14, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported...

Biohaven Pharmaceutical Blogs

September 2018 – Rimegepant at Migraine Trust International Symposium (MTIS)

Links to download the following presentations. Poster Presentation MTIS2018-170 Title: A Phase 1 Study to Evaluate the Bioequivalence of Oral Tablet and Orally Dissolving Tablet Formulations of Rimegepant, a Small Molecule CGRP Receptor Antagonist Date: Friday, September 7 – Saturday, September 8 Pr…

BIOHAVEN REPORTS POSITIVE RESULTS FROM DOUBLE-BLIND, PLACEBO-CONTROLLED, INVESTIGATOR INITIATED, PROOF OF CONCEPT TRIAL OF BHV-0223 FOR ANXIETY

BHV-0223 met its primary endpoint of improvement in anxiety compared to placebo during an anxiety-provoking speech task in patients diagnosed with social anxiety disorder and public speaking anxiety Trial results support further development of Biohaven’s glutamate modulating platform as a potential …

BIOHAVEN PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL AND RECENT BUSINESS RESULTS

Announced $150 million transaction with Royalty Pharma which supports Biohaven’s NDA filing activities for the oral CGRP antagonist program and to fund the Company’s portfolio into the fourth quarter of 2019 Reported data from two positive Phase 3 clinical trials with rimegepant for the acute treatm…

FIRST PATIENT ENROLLED IN BIOHAVEN’S PHASE 2/3 MILD-TO-MODERATE ALZHEIMER’S CLINICAL TRIAL

NEW HAVEN, Connecticut, August 1, 2018 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) (“Biohaven” or the “Company”) announced today that it has enrolled the first patient in a Phase 2/3 clinical trial of trigriluzole (BHV-4157), a novel glutamate modulator for the treatment…

BIOHAVEN RECEIVES FDA MAY PROCEEED LETTER AND INITIATES PHASE 2/3 CLINICAL TRIAL OF TRIGRILUZOLE (BHV-4157) IN ALZHEIMER’S DISEASE

NEW HAVEN, Connecticut, July 24, 2018 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) (“Biohaven” or the “Company”) announced today that it initiated a Phase 2/3 clinical trial of trigriluzole (BHV-4157), a novel glutamate modulator, in patients with mild-to-moderate Alzheim…

JUNE 2018 – RIMEGEPANT AT AMERICAN HEADACHE SOCIETY (AHS)

Downloads for oral presentations will be available after AHS presentation date/time, posters available at start of day. Late-breaking poster presentation PF116LB Title: A Phase 1 Study to Evaluate the Bioequivalence of Oral Tablet and Orally Dissolving Tablet Formulations of Rimegepant in Healthy Ad…
Show more

Biohaven Pharmaceutical Frequently Asked Questions

  • When was Biohaven Pharmaceutical founded?

    Biohaven Pharmaceutical was founded in 2014.

  • Who are Biohaven Pharmaceutical key executives?

    Biohaven Pharmaceutical's key executives are Declan Doogan, Vlad Coric and James Engelhart.

  • How many employees does Biohaven Pharmaceutical have?

    Biohaven Pharmaceutical has 754 employees.

  • Who are Biohaven Pharmaceutical competitors?

    Competitors of Biohaven Pharmaceutical include U.S. Stem Cell, Enanta Pharmaceuticals and Pfenex.

  • Where is Biohaven Pharmaceutical headquarters?

    Biohaven Pharmaceutical headquarters is located at 215 Church St, New Haven.

  • Where are Biohaven Pharmaceutical offices?

    Biohaven Pharmaceutical has an office in New Haven.

  • How many offices does Biohaven Pharmaceutical have?

    Biohaven Pharmaceutical has 1 office.